Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

A Large Cohort Study of 412 Patients with SRSF2/TET2 Co-Mutated Myeloid Neoplasms: The Molecular Landscape and Clinical Outcomes

Samuel G Cockey, Hailing Zhang, Mohammad Omar Hussaini, Ling Zhang, Lynn C. Moscinski, Ethan Yang, Jinming Song

Blood (2023) 142 (Supplement 1): 1882.

https://doi.org/10.1182/blood-2023-186967

Published: 2023

Journal Articles

B-Cell Maturation Antigen (BCMA) Expression and Clinical Features of Plasmablastic Lymphoma (PBL)

Ning Dong, Hailing Zhang, Jinming Song, Jamila Mammadova, Bijal D. Shah, Hayder Saeed, Ariel F. Grajales-Cruz, Leidy Lismeris Isenalumhe, Sameh Gaballa, Celeste M. Bello, Lubomir Sokol, Javier Pinilla-Ibarz, Julio C Chavez

Blood (2023) 142 (Supplement 1): 3138.

https://doi.org/10.1182/blood-2023-184779

Published: 2023

Journal Articles

Molecular Profiles and Clinical Features of Myeloproliferative Neoplasms Unclassifiable (MPN-U) with and without JAK2 / CALR / MPL Mutations

Curtis Gravenmier, Yumeng Zhang, Nagehan Pakasticali, Lynn C. Moscinski, Jinming Song, Ling Zhang

Blood (2022) 140 (Supplement 1): 12248–12249.

https://doi.org/10.1182/blood-2022-170665

Published: 2022

Journal Articles

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Blood (2022) 140 (Supplement 1): 3419–3421.

https://doi.org/10.1182/blood-2022-165802

Published: 2022

Journal Articles

Co-Existing ASXL1 and SF3B1 Mutations Carried Worse Outcome Than ASXL1 or SF3B1 Mutations Alone

Jinming Song, Lynn C. Moscinski, Ethan Yang, Mohammad Hussaini, Hailing Zhang

Blood (2022) 140 (Supplement 1): 4026–4027.

https://doi.org/10.1182/blood-2022-165241

Published: 2022

Journal Articles

Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway

Blood (2021) 138 (23): 2435–2440.

https://doi.org/10.1182/blood.2021012536

Published: 2021

Includes: Supplemental data

Journal Articles

Mutations Highly Specific for Secondary AML Are Associated with Poor Outcomes in Patients with NPM1 -Mutated ELN Favorable Risk AML

Onyee Chan, Najla Al Ali, Hammad Tashkandi, Austin Ellis, Somedeb Ball, Ling Zhang, Mohammad Hussaini, Jinming Song, Seongseok Yun, Chetasi Talati, Andrew T. Kuykendall, Eric Padron, David A. Sallman, Kendra Sweet, Rami S. Komrokji, Jeffrey E. Lancet

Blood (2021) 138 (Supplement 1): 686.

https://doi.org/10.1182/blood-2021-150759

Published: 2021

Journal Articles

Immune Profiles of Myeloma Tumor Microenvironment May Predict Sensitivity or Resistance to Elotuzumab

David Noyes, Melissa Alsina, Kenneth H. Shain, Rachid Baz, Taiga Nishihori, Jose Ochoa, Jinming Song, Jongphil Kim, Alexandra Achille, Jason Brayer

Blood (2021) 138 (Supplement 1): 2682.

https://doi.org/10.1182/blood-2021-151922

Published: 2021

Journal Articles

Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies

Quinto J Gesiotto, MD, David M Swoboda, MD, Najla E. Al Ali, Eric Padron, MD, Andrew T. Kuykendall, MD, Jinming Song, MD PhD, Chetasi Talati, MD, Kendra L. Sweet, MD MS, Jeffrey E. Lancet, MD, Rami Komrokji, MD, David A. Sallman, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140861

Published: 2020

Journal Articles

PTPN11 Mutations Are Associated with Poor Outcomes across Myeloid Malignancies

David M Swoboda, MD, Najla E. Al Ali, Eric Padron, MD, Andrew T. Kuykendall, MD, Jinming Song, MD PhD, Mohammad O Hussaini, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD MS, David A. Sallman, MD, Rami Komrokji, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140885

Published: 2020

Journal Articles

Molecular Insights into Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasm in Patients with Multiple Myeloma and Cytopenia(s)

Jinming Song, MD PhD, Hailing Zhang, MD, Xiaohui Zhang, MD PhD, Mohammad Hussaini, MD, Ning Dong, MD, Lynn C Moscinski, Kenneth H. Shain, MD PhD, Melissa Alsina, MD, Taiga Nishihori, MD, Ling Zhang, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141656

Published: 2020

Journal Articles

RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation

Onyee Chan, MD, Chetasi Talati, MD, Hannah H Asghari, MD, Jinming Song, MD PhD, Mohammad Hussaini, MD, Andrew T Kuykendall, MD, David A Sallman, MD, Eric Padron, MD, Rami S. Komrokji, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Asmita Mishra, MD, Kendra L. Sweet, MD

Blood (2019) 134 (Supplement_1): 2052.

https://doi.org/10.1182/blood-2019-129742

Published: 2019

Journal Articles

Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome

Blood (2019) 134 (Supplement_1): 4621.

https://doi.org/10.1182/blood-2019-130922

Published: 2019

Journal Articles

Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation

Onyee Chan, MD, Anthony Hunter, MD, Chetasi Talati, MD, David A Sallman, MD, Hannah Asghari, MD BS, Jinming Song, MD PhD, Mohammad Hussaini, MD, Nelli Bejanyan, MD, Hany Elmariah, MD MS, Andrew T Kuykendall, MD, Eric Padron, MD, Rami S. Komrokji, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD, Asmita Mishra, MD

Blood (2019) 134 (Supplement_1): 149.

https://doi.org/10.1182/blood-2019-131530

Published: 2019

Journal Articles

The Prognostic Significance of ASXL1/EZH2 Co-Mutation in Comparison with ASXL1 or EZH2 Mutation Alone in Myelodysplastic Syndromes

Pukhraz Basra, MBBS, David Gajzer, MD, Mohammad O Hussaini, MD, Hailing Zhang, MD, Lynn C. Moscinski, MD, Eric Padron, MD, David A Sallman, MD, Rami S. Komrokji, MD, Ling Zhang, MD, Jinming Song, MD PhD

Blood (2019) 134 (Supplement_1): 5428.

https://doi.org/10.1182/blood-2019-132070

Published: 2019

Journal Articles

SF3B1/DNMT3A Double Mutations Are Associated with Better Prognosis Than DNMT3A Mutation Alone in Myeloid Neopasms

Jinming Song, MD PhD, Mohammad Hussaini, MD, Lynn C. Moscinski, MD, Ling Zhang, MD, Xiaohui Zhang, MD PhD, Haipeng Shao, MD, Hailing Zhang, MD

Blood (2019) 134 (Supplement_1): 5029.

https://doi.org/10.1182/blood-2019-124040

Published: 2019

Journal Articles

Genetic and Clinical Features of Chronic Myelmonocytic Leukemia with Fibrosis

Mohammad O Hussaini, MD, Jinming Song, MD PhD, Andrew T Kuykendall, MD, David A Sallman, MD, Eric Padron, MD, Rami S. Komrokji, MD, Sayeef Mirza, MDMPH, Ling Zhang, MD

Blood (2019) 134 (Supplement_1): 5442.

https://doi.org/10.1182/blood-2019-128997

Published: 2019

Journal Articles

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

Taiga Nishihori, MD, Rachid Baz, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Frederick L. Locke, MD, Jongphil Kim, PhD, Jinming Song, MD PhD, Michael Dumala, Melissa Alsina, MD

Blood (2019) 134 (Supplement_1): 3189.

https://doi.org/10.1182/blood-2019-131451

Published: 2019

Journal Articles

Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts

David M Swoboda, MD, Jung-Hoon Lee, MD, Onyee Chan, MD, Rami S. Komrokji, MD, Najla Al Ali, M.Sc, Eric Padron, MD, Alan F. List, MD, Mohammad O Hussaini, MD, Jinming Song, MD PhD, David A Sallman, MD

Blood (2019) 134 (Supplement_1): 4244.

https://doi.org/10.1182/blood-2019-124772

Published: 2019

Journal Articles

Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival

David A Sallman, MD, Najla Al Ali, M.Sc, Seongseok Yun, MD PhD, Eric Padron, MD, Jinming Song, MD PhD, Mohammad Omar Hussaini, MD, Chetasi Talati, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2018) 132 (Supplement 1): 1817.

https://doi.org/10.1182/blood-2018-99-117297

Published: 2018

NARROW

A Large Cohort Study of 412 Patients with SRSF2/TET2 Co-Mutated Myeloid Neoplasms: The Molecular Landscape and Clinical Outcomes

B-Cell Maturation Antigen (BCMA) Expression and Clinical Features of Plasmablastic Lymphoma (PBL)

Molecular Profiles and Clinical Features of Myeloproliferative Neoplasms Unclassifiable (MPN-U) with and without JAK2 / CALR / MPL Mutations

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Co-Existing ASXL1 and SF3B1 Mutations Carried Worse Outcome Than ASXL1 or SF3B1 Mutations Alone

Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway

Mutations Highly Specific for Secondary AML Are Associated with Poor Outcomes in Patients with NPM1 -Mutated ELN Favorable Risk AML

Immune Profiles of Myeloma Tumor Microenvironment May Predict Sensitivity or Resistance to Elotuzumab

Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies

PTPN11 Mutations Are Associated with Poor Outcomes across Myeloid Malignancies

Molecular Insights into Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasm in Patients with Multiple Myeloma and Cytopenia(s)

RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation

Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome

Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation

The Prognostic Significance of ASXL1/EZH2 Co-Mutation in Comparison with ASXL1 or EZH2 Mutation Alone in Myelodysplastic Syndromes

SF3B1/DNMT3A Double Mutations Are Associated with Better Prognosis Than DNMT3A Mutation Alone in Myeloid Neopasms

Genetic and Clinical Features of Chronic Myelmonocytic Leukemia with Fibrosis

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts

Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only